Extension Study to Evaluate the Safety of Q8003 in Patients With Acute Moderate to Severe Pain
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3 double-blind, multiple dose safety extension study of Q8003 administered at
daily doses up to 36 mg morphine/24 mg oxycodone (Q8003 36mg/24mg) over a treatment period of
up to 4 weeks. Patients with acute moderate to severe pain who have completed participation
in one of the designated QRxPharma, Inc. acute pain lead-in studies will be eligible for this
trial.